glp 1 and adhd meds GLP-1 drugs tied to lower brain inflammation, higher depression risk GLP-1s, ADHD, & OCD: Stimulants

not therapeutic claims

Policy changes like the Inflation Reduction Acts $2,000 out-of-pocket (OOP) cap for Medicare Part D beneficiaries may offer some relief, as patients who reach the cap pay $0 thereafter, but they also risk prompting payers to tighten coverage for high-cost drugs, especially those indicated for obesity

Random lasing with a high degree of circular dichroism by chiral plasmonic gold nanoparticles

Claims Drawing Regulatory Attention FDA has indicated that compounded products generally should not be promoted using claims that: Suggest FDA approval Imply therapeutic equivalence Claim generic status without approval Guarantee clinical outcomes Misrepresent safety profiles Compare performance to approved products without evidence Marketing communications must be carefully reviewed to avoid misleading representations

Copper binding occurs through histidine imidazole nitrogen and N-terminal amino group, forming stable 1:1 complex